Results 311 to 320 of about 17,208,238 (361)

Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

Ca-A Cancer Journal for Clinicians, 2020
Grace M Choong, Grace D Cullen, Ciara C O'sullivan   +2 more
exaly  

Drug-receptor interactions and drug design

Trends in Pharmacological Sciences, 1988
openaire   +2 more sources

Innovations in research and clinical care using patient‐generated health data

Ca-A Cancer Journal for Clinicians, 2020
H S L Jim, Aasha I Hoogland, Naomi C Brownstein   +2 more
exaly  

WHAT IF: a molecular modeling and drug design program.

Journal of Molecular Graphics, 1990
G. Vriend
semanticscholar   +1 more source

Current recommendations and recent progress in endometrial cancer

Ca-A Cancer Journal for Clinicians, 2019
Gini F Fleming
exaly  

Recent progress in pancreatic cancer

Ca-A Cancer Journal for Clinicians, 2013
Christopher L Wolfgang, Daniel A Laheru, Elliot Fishman   +2 more
exaly  

Designer drugs.

Texas medicine, 1989
Designer drugs are synthetic analogs of substances with known psychoactive properties. These analogs are dangerous due to their direct pharmacological effects and the presence of toxic by-products that occur during synthesis. Three groups of designer drugs are reviewed (fentanyl, meperidine, and methamphetamine analogs), and their psychoactive effects ...
openaire   +1 more source

Hodgkin lymphoma: A review and update on recent progress

Ca-A Cancer Journal for Clinicians, 2018
Satish P Shanbhag, Richard F Ambinder
exaly  

Using PyMOL as a platform for computational drug design

, 2017
Shuguang Yuan, H. C. S. Chan, Zhenquan Hu   +2 more
semanticscholar   +1 more source

Immunotherapy of cancer in 2012

Ca-A Cancer Journal for Clinicians, 2012
Lisa H Butterfield, Ahmad A Tarhini
exaly